Pfizer Initiates First Phase III Non-Small Cell Lung Cancer Study with IGF-1R Compound
Pfizer Oncology yesterday announced the initiation of a Phase III, global, open-label, randomized, first-line clinical trial to determine whether the addition of CP-751,871 in combination with carboplatin and paclitaxel prolongs survival (overall survival) in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology (e.g., squamous, large cell and adenosquamous histologies).
CP‑751,871 is a selective fully human monoclonal antibody against the insulin‑like growth factor 1 receptor (IGF‑1R) pathway. Through this inhibition, CP-751,871 blocks one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumor cells. This is the first Phase III study (1016) to examine the promising mechanism of action of IGF-1R in patients with non-adenocarcinoma NSCLC, an underserved patient population who have not benefited from recent treatment advances.
This entry was posted on Friday, April 18th, 2008 at 12:03 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.